ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

As previously reported on our Current Report on Form 8-K filed July 28, 2017, simultaneous with an equity investment of $4 million by John Schutte (“Investor”), we and Essex Woodlands Health Ventures V, L.P. (“Essex”) agreed to amend and restate the existing Voting Agreement among parties, including Galen Partners III, LP (“Galen”), Essex and us, to provide for Investor to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Investor is a principal of Mainpointe LLC, a Kentucky limited liability company (“Mainpointe”). Mainpointe is a licensee of the Registrant’s Impede^® technology.

On July 28, 2017 the Second Amended and Restated Voting Agreement between us, Essex, Galen, and Investor became effective upon receipt of Galen’s . The fully executed Second Amended and Restated Voting Agreement is attached hereto as Exhibit 10.1.

Item 9.01. Financial Statements and Exhibits

Exhibit

ACURA PHARMACEUTICALS, INC Exhibit
EX-10.1 2 v471981_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1   SECOND AMENDED AND RESTATED VOTING AGREEMENT   This SECOND AMENDED AND RESTATED VOTING AGREEMENT (this “Agreement”) dated as of July 24,…
To view the full exhibit click here

About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.